Hemoglobin glutamer-250 (bovine) - HbO2 Therapeutics

Drug Profile

Hemoglobin glutamer-250 (bovine) - HbO2 Therapeutics

Alternative Names: Bovine haemoglobin - HbO2 Therapeutics; Bovine hemoglobin - OPK Biotech; HBOC-201; Hemoglobin glutamer-250 - HbO2 Therapeutics; Hemopure

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biopure Corporation
  • Developer Biopure Corporation; HbO2 Therapeutics
  • Class Haemoglobins
  • Mechanism of Action Haemoglobin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Ischaemia; Shock

Most Recent Events

  • 28 Feb 2017 No development reported - Phase-II for Anaemia in Greece (IV) (NCT00301535)
  • 26 Jun 2015 Phase-II clinical trials in Ischaemia in South Africa, Europe (IV)
  • 26 Jun 2015 Phase-II clinical trials in Shock in South Africa (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top